Stay updated with breaking news from Dror Ben Asher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
.jpg)
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
TEL AVIV, Israel and RALEIGH, N.C., May 27, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the first quarter ended March 31, 2021. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19 therapeutics development. Opaganib, one of the most advanced and promising novel, dual-mode of action, oral drug candidates in development for COVID-19, now ...
Five Israeli teams fighting for a COVID-19 cure Posted on Israeli scientists and researchers are racing to find a cure for COVID-19, as global consensus is forming among medical professionals that vaccination is not going to eliminate corona. When Israel launched its mass vaccination campaign, there were many who believed there would no longer be a need for medication, Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, told The Jerusalem Post. “Now we know that this was an illusion,” he said. “Even in Israel, no...
-in -class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 ( upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102 ( Bekinda ®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from...
Share this article TEL AVIV, Israel and RALEIGH, N.C,, Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), announced that it had successfully completed their Phase 2 Proof-of-Concept (POC) clinical trial of Rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). As part of an exclusive license agreement between RedHill and Cosmo from October 2019 for the U.S. rights to Aemcolo ® (rifamycin...